Scholars Central

Research articlePublished 3 May 2019

Discovery of potential xanthine oxidase inhibitors using in silico docking studies

Authors: Muthuswamy Umamaheswari, Arumugam Madeswaran, Kuppusamy Asokkumar, Thirumalaisamy Sivashanmugam, Varadharajan Subhadradevi, Puliyath Jagannath

Der Pharma Chemica

Volume 3 · Issue 5 · Pages 240–247

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

New drugs for the inhibition of the enzyme xanthine oxidase are in development and they have to be screened before being considered for preclinical and clinical evaluation. In order to understand the mechanism of ligand binding and to identify potent xanthine oxidase inhibitors, a study involving molecular docking and virtual screening has been performed. The objective of the current study is to evaluate the xanthine oxidase inhibitory activity of flavonoids using in silico docking studies. In this perspective, flavonoids like Butein, Fisetin, Diosmetin, Tricetin, Genistein, Tricin, Vitexycarpin, Herbacetin, Biochanin, Rhamnetin, Isorhamnetin, Robinetin, Peonidin and Okanin were selected. Allopurinol, a known xanthine oxidase inhibitor was used as the standard. In silico docking studies were carried out using AutoDock 4.2, based on the Lamarckian genetic algorithm principle. The three important parameters like binding energy, inhibition constant and intermolecular energy were determined. The results showed that all the selected flavonoids showed lesser binding energy ranging between -7.86 kcal/mol to -5.40 kcal/mol when compared with that of the standard (-4.47 kcal/mol). Intermolecular energy (-9.95 kcal/mol to -7.49 kcal/mol) and inhibition constant (1.72 μM to 110.19 μM) of the ligands also coincide with the binding energy. All the selected flavonoids consist of benzopyran ring in its basic nucleus, which would have contributed to its xanthine oxidase inhibitory activity. These molecular docking analyses could lead to the further development of potent xanthine oxidase inhibitors for the prevention and treatment of gout and related inflammatory conditions.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Der Pharma Chemica.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDer Pharma Chemica
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Muthuswamy Umamaheswari”
  • BylineArticles whose byline prints “Arumugam Madeswaran”
  • BylineArticles whose byline prints “Kuppusamy Asokkumar”
  • BylineArticles whose byline prints “Thirumalaisamy Sivashanmugam”
  • BylineArticles whose byline prints “Varadharajan Subhadradevi”
  • BylineArticles whose byline prints “Puliyath Jagannath”